查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995361

造影輸液設備市場：按模式、移動性、最終用戶和應用分類的全球市場預測，2026-2032年

Contrast Media Injectors Market by Modality, Mobility, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，造影劑注射器市場價值將達到 21.9 億美元，到 2026 年將成長至 23.7 億美元，到 2032 年將達到 38.2 億美元，複合年成長率為 8.23%。

主要市場統計數據
基準年 2025 21.9億美元
預計年份：2026年 23.7億美元
預測年份 2032 38.2億美元
複合年成長率 (%) 8.23%

權威說明指出，最新的造影劑注射器正在重新定義手術流程的一致性、安全性和跨部門臨床工作流程。

造影劑輸液設備在影像精確度、手術效率和病患安全之間起著至關重要的作用。這些裝置控制造影劑的流速和劑量，從而支援各種診斷和介入手術中的高解析度成像。過去十年，臨床期望已不再局限於簡單的輸注性能，而是要求具備整合智慧、可重複輸注以及與影像系統和醫院IT基礎設施的無縫整合。

智慧、便攜、互通性和永續性的軟體技術如何融合，從而重塑注射器設計、臨床部署和採購重點？

在技​​術整合、臨床需求和更廣泛的醫療保健系統優先事項的推動下，造影劑輸液設備領域正經歷著一場變革。自動化和軟體智慧發揮核心作用，輸液設備正從單純的機器演變為能夠調整給藥通訊協定、檢索手術元元資料並與影像系統主機和電子健康記錄整合的平台解決方案。這種轉變實現了可重複的影像通訊協定，加快了臨床醫生對系統的接受度，並降低了操作者之間的差異。

2025 年關稅措施對全球採購、供應商多元化、產品架構以及整個注射​​器供應鏈的採購韌性的策略影響。

美國於2025年實施並提高的關稅對造影劑注射器及其組件的供應鏈、籌資策略和價格談判動態產生了下游影響。許多製造商依賴全球採購的精密零件、一次性拋棄式產品和子組件，這些產品的成本結構極易受到進口關稅的影響。由於關稅提高導致海外製造零件的進口成本飆升，製造商和供應商已採取一系列措施來調整供應關係和採購計劃。

以模式、移動性、最終用戶需求和特定應用需求為主導產品藍圖和臨床證據策略。

穩健的市場區隔觀點清楚地闡明了不同設備配置和操作環境下的多樣化臨床需求和商業性機會。基於影像方式，市場可細分為電腦斷層掃描 (CT)、磁振造影(MRI)、正子斷層掃描 (PET)、超音波和放射成像等領域，每種影像方式對注射時機、造影劑相容性和與影像擷取的同步性都有其獨特的要求。在電腦斷層掃描 (CT) 工作流程中，快速大劑量投藥和多期注射時機的精確性至關重要；而磁振造影(MRI) 則需要與钆基造影劑相容，並在特定序列中具備長時間注射能力。正子斷層掃描 (PET) 和超音波具有獨特的操作特性，會影響注射器的控制和使用者介面。

區域醫療保健重點、法規環境和製造地如何影響全球市場的部署模式和籌資策略？

區域趨勢對整個造影劑輸液設備市場的採用模式、監管重點和供應鏈策略有顯著影響。在美洲，對先進診斷技術的投資以及眾多高通量成像中心的普及，推動了對整合系統、強大的服務網路以及優先考慮運轉率和總體擁有成本的合約模式的需求。報銷機制和醫院採購週期決定了採購時機，而國內生產能力則影響著抵禦跨境關稅風險的能力。

競爭的動態是由硬體的穩健性、軟體的差異化、服務生態系統和策略夥伴關係所驅動的，這些因素決定了永續的商業性優勢。

輸液設備產業的競爭動態以成熟的醫療設備原始設備製造商 (OEM)、專注於特定細分領域的創新企業以及專業服務供應商之間的互動為特徵。成熟的製造商利用其豐富的產品系列、強大的服務網路和規模經濟優勢，提供將輸液設備與影像系統和企業 IT 整合的綜合解決方案。這些公司通常會投資於長期臨床證據的累積、多中心試驗以及跨學科合作，以鞏固其產品在醫院採購決策中的競爭力。

製造商和醫療保健系統可採取的策略重點：協調產品架構、供應鏈彈性、臨床證據和商業模式，以獲得永續的競爭優勢。

產業領導企業可以透過整合產品、營運和商業性舉措，採取果斷行動來確保競爭優勢。首先，應優先考慮模組化產品架構，允許分階段升級軟體和耗材，而無需完全更換硬體。這可以降低採購門檻，並保障耗材的持續收入。此外，還應投資於安全的互通性功能以及與影像主機、RIS/PACS 和電子健康記錄的標準化整合，以簡化部署並減少 IT 摩擦。

採用透明、多方面的研究途徑，結合訪談、設備基準測試、監管審查和供應鏈分析，得出了可操作的產業見解。

本分析的研究途徑結合了多方面的定性研究以及對技術、法規和臨床文獻的系統性回顧。主要研究包括對臨床負責人、生物醫學工程師、採購主管和醫療設備服務經理進行結構化訪談，以直接了解工作流程需求、維護注意事項以及影響採購決策的因素。除訪談外，還針對具有代表性的注射器平台進行了有針對性的儀器基準測試，以評估其人體工學、流量控制精度、介面設計和耗材管理。

簡要概述技術、臨床和供應鏈因素如何融合，從而重新定義輸液設備的價值提案和採購要求。

造影劑輸液設備正從專用硬體發展成為整合式臨床平台，影響影像品質、手術效率和病患安全。這一發展趨勢受到軟體智慧進步、便攜性和模組化需求、對臨床證據日益成長的期望以及全球供應鏈和區域法規環境等因素的影響。這些因素共同促使製造商和醫療系統採取更全面的產品開發、採購和生命週期支援方法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：造影劑輸液設備市場：依注射方式分類

  • 電腦斷層掃描
  • 磁振造影
  • 正子斷層掃描
  • 超音波
  • X光影像診斷

第9章：依安裝類型造影的顯影劑輸液設備市場

  • 可攜式的
  • 固定式

第10章：造影劑輸液設備市場：依最終用戶造影

  • 門診部
  • 診斷中心
  • 醫院
  • 研究機構

第11章：造影劑輸液設備市場：依應用領域造影

  • 循環系統
    • 介入性心臟病學
    • 非介入性心臟病學
  • 胃腸病學
    • CT造影
    • 磁振造影胰造影
  • 神經病學
    • 中風影像診斷
    • 腫瘤診斷
  • 腫瘤學
  • 整形外科

第12章：造影劑輸液設備市場：依地區造影

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：造影劑輸液設備市場：依組別造影

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：造影劑輸液設備市場：依國家造影

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國造影劑輸液設備市場

第16章：中國造影劑輸液設備市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Apollo Rt Co. Ltd.
  • Bayer AG
  • Debiotech SA
  • GE Healthcare
  • Guerbet, LLC
  • Leriva SA
  • MEDTRON AG
  • Nemoto Kyorindo Co., Ltd.
  • Ulrich GmbH & Co. KG
  • Vygon SAS
Product Code: MRR-6611A51116E5

The Contrast Media Injectors Market was valued at USD 2.19 billion in 2025 and is projected to grow to USD 2.37 billion in 2026, with a CAGR of 8.23%, reaching USD 3.82 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.19 billion
Estimated Year [2026] USD 2.37 billion
Forecast Year [2032] USD 3.82 billion
CAGR (%) 8.23%

An authoritative orientation to how modern contrast media injectors redefine procedural consistency, safety, and cross-departmental clinical workflows

Contrast media injectors occupy a pivotal role at the intersection of imaging precision, procedural efficiency, and patient safety. These devices deliver contrast agents with controlled flow rates and volumes to support high-resolution visualization across a broad spectrum of diagnostic and interventional procedures. Over the past decade clinical expectations have evolved beyond mere delivery performance to demand integrated intelligence, reproducible dosing, and seamless connectivity with imaging systems and hospital IT infrastructures.

Clinical workflows increasingly emphasize repeatability and minimized variability in contrast administration because image quality and diagnostic confidence are directly affected by injection protocols. As radiology departments and interventional suites adapt to higher throughput and more complex hybrid procedures, injectors are expected to support multi-phase protocols, automated sequences, and fail-safe safeguards that reduce human error. Concurrently, infection control imperatives and single-use component trends are reshaping device design and disposables strategy.

The industry landscape is shaped by converging pressures from clinicians, procurement professionals, and regulators. Clinicians demand precision and integration with modality workflows; procurement seeks total cost of ownership and service reliability; regulators emphasize patient safety and sterility assurance. Together, these drivers are catalyzing innovation in ergonomics, software-enabled dosing, modular hardware, and lifecycle support, positioning contrast media injectors as strategic assets within imaging care pathways.

How software intelligence, portability, interoperability, and sustainability are converging to reshape injector design, clinical adoption, and procurement priorities

The contrast media injector landscape is undergoing transformative shifts driven by technological integration, clinical expectations, and broader healthcare system priorities. Automation and software intelligence have become central, with injectors evolving from mechanical devices into platform solutions that orchestrate dosing protocols, capture procedure metadata, and interface with modality consoles and electronic health records. This transition enables reproducible imaging protocols, accelerates onboarding for clinicians, and reduces variability across operators.

Another important shift is the move toward portability and modularity. Advances in battery technology, compact pump designs, and ruggedized housings are enabling portable injectors to support point-of-care imaging and interventional procedures outside traditional radiology suites. At the same time, stationary systems are being reimagined with modular disposables and serviceable components to improve uptime and lower lifecycle costs. Sustainability considerations are prompting manufacturers to redesign disposables and packaging to reduce medical waste while preserving sterility.

Regulatory scrutiny and the demand for evidence-based adoption have driven manufacturers to invest more in clinical validation and real-world performance data. Interoperability standards and cybersecurity expectations are reshaping product roadmaps, requiring secure connectivity and robust software lifecycle management. Finally, the convergence of imaging modalities and hybrid procedures elevates the injector's role in multidisciplinary care, necessitating designs that accommodate diverse contrast requirements and clinical workflows.

The strategic implications of 2025 tariff measures on global sourcing, supplier diversification, product architecture, and procurement resilience across injector supply chains

The introduction and escalation of United States tariffs in 2025 created downstream effects that reverberated across supply chains, procurement strategies, and price negotiation dynamics for contrast media injectors and their components. Many manufacturers rely on globally sourced precision components, single-use disposables, and subassemblies whose cost structures were sensitive to import duties. As tariffs increased landed costs for components manufactured abroad, manufacturers and suppliers responded with a range of measures that altered supply relationships and procurement timelines.

One common response was supplier diversification and nearshoring. Procurement teams accelerated qualification of alternative vendors in lower-cost or tariff-exempt jurisdictions and increased inventory buffers to protect against cost volatility. Where nearshoring was not feasible, some manufacturers absorbed short-term cost increases to preserve market positioning, while others implemented price adjustments or restructured contracts with health system customers. These reactions had cascading effects on service contracts, warranty terms, and capital procurement cycles for hospitals and imaging centers.

Tariff pressures also intensified focus on product architecture optimization. Companies revisited bill-of-materials to identify components amenable to redesign or domestic sourcing, and they examined the potential for greater vertical integration of high-value subassemblies. For end users, total cost considerations extended beyond acquisition price to include spare parts availability, maintenance logistics, and consumables sourcing. In aggregate, the tariff environment catalyzed a strategic reassessment of sourcing resilience, supplier partnerships, and cross-border manufacturing footprints that will continue to influence procurement and product roadmaps.

Segment-driven product roadmaps and clinical evidence strategies informed by modality, mobility, end-user requirements, and application-specific procedural needs

A robust segmentation perspective clarifies the varied clinical requirements and commercial opportunities across different device configurations and use environments. Based on Modality, market is studied across Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound, and X-Ray Imaging, each of which imposes unique demands on injection timing, contrast formulation compatibility, and synchronization with image acquisition. Computed Tomography workflows prioritize rapid bolus delivery and multi-phase timing precision, whereas Magnetic Resonance Imaging requires compatibility with gadolinium-based agents and extended infusion capabilities for certain sequences. Positron Emission Tomography and Ultrasound bring their own procedural nuances that influence injector controls and user interfaces.

Mobility considerations are equally important, and Based on Mobility, market is studied across Portable and Stationary, reflecting differing tradeoffs between compactness, battery life, duty cycle, and integrated safety features. Portable injectors must balance lightweight construction with robust flow control, making them suitable for interventional suites, intensive care settings, and bedside procedures. Stationary injectors, by contrast, can emphasize higher throughput, integrated disposables management, and deeper modality integration for high-volume imaging centers.

End-user segmentation informs service and business models, and Based on End User, market is studied across Ambulatory Care Centers, Diagnostic Centers, Hospitals, and Research Institutes, each with distinctive procurement cycles and operational priorities. Ambulatory care centers often prioritize cost efficiency and compact footprints, diagnostic centers pursue throughput and uptime, hospitals demand enterprise integration and extended warranty terms, and research institutes require experimental flexibility and precise dosing control. Application-level segmentation further refines product requirements and clinical evidence needs; Based on Application, market is studied across Cardiology, Gastroenterology, Neurology, Oncology, and Orthopedics. Cardiology is further studied across Interventional Cardiology and Non-Interventional Cardiology, reflecting differing procedural environments and contrast demands. Gastroenterology is further studied across Computed Tomography Colonography and Magnetic Resonance Cholangiopancreatography, which drive specific injector timing and contrast protocols. Neurology is further studied across Stroke Imaging and Tumor Diagnostics, where timing precision and reproducibility are paramount for diagnostic sensitivity.

Integrating these segmentation layers enables product teams to prioritize development pathways, tailor training and service offers, and craft differentiated value propositions that resonate with distinct clinical workflows and procurement expectations.

How regional healthcare priorities, regulatory environments, and manufacturing footprints shape adoption patterns and procurement strategies across global markets

Regional dynamics exert a strong influence on adoption patterns, regulatory priorities, and supply-chain strategies across the contrast media injector landscape. In the Americas, investment in advanced diagnostics and a large installed base of high-throughput imaging centers drives demand for integrated systems, rigorous service networks, and contractual models that emphasize uptime and total cost of ownership. Reimbursement frameworks and hospital procurement cycles shape purchasing cadences, and domestic manufacturing capacity influences resilience to cross-border tariff exposure.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and varying levels of healthcare infrastructure create a diverse set of opportunities and challenges. Western European healthcare systems emphasize clinical evidence, interoperability, and lifecycle support, whereas markets in parts of the Middle East and Africa prioritize cost efficiency, durability in challenging operating environments, and ease of maintenance. Regulatory harmonization efforts in certain jurisdictions accelerate device approvals but also require tailored market access strategies.

Asia-Pacific presents a dual landscape of advanced centers in metropolitan areas and rapidly expanding imaging capacity in emerging markets. High-growth urban hospitals demand cutting-edge integration and high throughput, while cost-sensitive facilities in secondary cities seek scalable solutions and reliable service networks. Manufacturing hubs in the region support component availability but also introduce competitive local suppliers, which influences pricing and partnership strategies. Across all regions, regional standards for infection control, single-use consumables, and environmental disposal are reshaping product designs and aftermarket services.

Competitive dynamics driven by hardware robustness, software differentiation, service ecosystems, and strategic partnerships that define sustained commercial advantage

Competitive dynamics in the injector space are characterized by the interplay of established medical device OEMs, focused niche innovators, and specialized service providers. Established manufacturers leverage broad product portfolios, deep service networks, and scale to offer comprehensive solutions that integrate injectors with imaging modality ecosystems and enterprise IT. These firms often invest in long-term clinical evidence generation, multi-site trials, and cross-disciplinary engagement to anchor their products in hospital procurement decisions.

Niche innovators differentiate through software capabilities, user experience, and tailored disposables that address specific procedural needs, such as interventional cardiology or neurovascular imaging. Their agility enables rapid iteration of user interfaces and protocol libraries, which can accelerate clinical adoption in specialized centers. Service providers and third-party manufacturers play a critical role in aftermarket support, offering consumables, preventive maintenance, and refurbishment services that extend device lifecycles and reduce total ownership costs for customers.

Strategic partnerships and licensing agreements between device makers, software vendors, and imaging system integrators are increasingly important. Collaboration enables deeper interoperability, streamlined workflow handoffs, and bundled service models that appeal to enterprise purchasers. Competitive differentiation now rests on the ability to combine robust hardware performance with secure connectivity, evidence-backed protocols, and scalable service models that reduce operational friction for clinical teams.

Actionable strategic priorities for manufacturers and health systems that align product architecture, supply resilience, clinical evidence, and commercial models for sustainable advantage

Industry leaders can act decisively to secure advantage through a combination of product, operational, and commercial initiatives. First, prioritize modular product architectures that permit incremental upgrades to software and disposables without full hardware replacement; this reduces procurement barriers and supports recurring consumables revenue. Invest in secure interoperability features and standardized integration with imaging consoles, RIS/PACS, and electronic health records to simplify adoption and reduce IT friction.

Strengthen supply-chain resilience by diversifying qualified suppliers, nearshoring critical subassemblies where feasible, and building flexible inventory strategies that mitigate tariff or disruption risk. Complement sourcing strategies with transparent lifecycle support offerings, including predictive maintenance and outcome-linked service contracts that align vendor incentives with clinical uptime objectives. Accelerate clinical evidence generation through multi-center studies and real-world data collection that demonstrate reproducibility, safety, and workflow efficiency in target applications such as interventional cardiology and stroke imaging.

Finally, engage customers with holistic commercial models that combine device, consumables, training, and data insights. Offer tailored financing and pilot programs to lower adoption friction for ambulatory centers and diagnostic clinics, while providing enterprise agreements that deliver predictable service outcomes for hospitals. By aligning product design, evidence, and commercial models, companies can translate technological differentiation into measurable clinical and financial value.

A transparent multi-method research approach combining interviews, device benchmarking, regulatory review, and supply-chain mapping to generate actionable industry insights

The research approach underpinning this analysis combined multi-method qualitative inquiry with systematic review of technical, regulatory, and clinical literature. Primary research consisted of structured interviews with clinical leaders, biomedical engineers, procurement executives, and device service managers to capture first-hand insights into workflow requirements, maintenance considerations, and procurement decision drivers. These interviews were complemented by targeted device benchmarking to evaluate ergonomics, flow control precision, interface design, and disposables management across representative injector platforms.

Secondary research included review of regulatory guidance, standards for infusion devices, published clinical protocols, and peer-reviewed studies that examine the relationship between contrast administration and imaging outcomes. Supply-chain mapping exercises identified key upstream component dependencies, regional manufacturing hubs, and logistics considerations that influence lead times and risk exposure. Scenario analysis was used to explore the operational and financial implications of supply-chain disruptions and policy shifts, and findings were triangulated across data sources to ensure robustness and practical relevance.

Throughout the research process emphasis was placed on capturing actionable insights rather than predictive estimates, prioritizing evidence that supports product design decisions, procurement strategies, and clinical implementation pathways for users and manufacturers alike.

A concise synthesis of how technological, clinical, and supply-chain forces converge to redefine injector value propositions and procurement imperatives

Contrast media injectors are transitioning from specialized hardware into integrated clinical platforms that influence imaging quality, procedural efficiency, and patient safety. This evolution is being shaped by advances in software intelligence, demand for portability and modularity, rising expectations for clinical evidence, and the practical realities of global supply chains and regional regulatory environments. Together, these forces require manufacturers and health systems to adopt more holistic approaches to product development, procurement, and lifecycle support.

Effective strategies will combine product architectures that support incremental upgrades, robust interoperability for seamless workflow integration, and commercial models that align incentives around uptime and clinical outcomes. Supply-chain resilience and regional manufacturing considerations will continue to influence sourcing decisions and pricing strategies, particularly in environments affected by policy changes or tariff pressure. Finally, targeted clinical validation and real-world data collection will remain essential to demonstrate value across distinct modalities, mobility profiles, end users, and applications.

By applying the segmentation and regional perspectives outlined in this summary, stakeholders can better prioritize investments, craft differentiated offerings, and implement procurement strategies that reduce operational risk while enhancing diagnostic and interventional care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Contrast Media Injectors Market, by Modality

  • 8.1. Computed Tomography
  • 8.2. Magnetic Resonance Imaging
  • 8.3. Positron Emission Tomography
  • 8.4. Ultrasound
  • 8.5. X-Ray Imaging

9. Contrast Media Injectors Market, by Mobility

  • 9.1. Portable
  • 9.2. Stationary

10. Contrast Media Injectors Market, by End User

  • 10.1. Ambulatory Care Centers
  • 10.2. Diagnostic Centers
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Contrast Media Injectors Market, by Application

  • 11.1. Cardiology
    • 11.1.1. Interventional Cardiology
    • 11.1.2. Non-Interventional Cardiology
  • 11.2. Gastroenterology
    • 11.2.1. Computed Tomography Colonography
    • 11.2.2. Magnetic Resonance Cholangiopancreatography
  • 11.3. Neurology
    • 11.3.1. Stroke Imaging
    • 11.3.2. Tumor Diagnostics
  • 11.4. Oncology
  • 11.5. Orthopedics

12. Contrast Media Injectors Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Contrast Media Injectors Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Contrast Media Injectors Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Contrast Media Injectors Market

16. China Contrast Media Injectors Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Apollo Rt Co. Ltd.
  • 17.6. Bayer AG
  • 17.7. Debiotech S.A.
  • 17.8. GE Healthcare
  • 17.9. Guerbet, LLC
  • 17.10. Leriva SA
  • 17.11. MEDTRON AG
  • 17.12. Nemoto Kyorindo Co., Ltd.
  • 17.13. Ulrich GmbH & Co. KG
  • 17.14. Vygon SAS

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONTRAST MEDIA INJECTORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CONTRAST MEDIA INJECTORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CONTRAST MEDIA INJECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CONTRAST MEDIA INJECTORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY X-RAY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY X-RAY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY X-RAY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY PORTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY STATIONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY STATIONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY STATIONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY NON-INTERVENTIONAL CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY NON-INTERVENTIONAL CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY NON-INTERVENTIONAL CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY COMPUTED TOMOGRAPHY COLONOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY COMPUTED TOMOGRAPHY COLONOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY COMPUTED TOMOGRAPHY COLONOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY STROKE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY STROKE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY STROKE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY TUMOR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY TUMOR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY TUMOR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CONTRAST MEDIA INJECTORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE CONTRAST MEDIA INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST CONTRAST MEDIA INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CONTRAST MEDIA INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN CONTRAST MEDIA INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. GCC CONTRAST MEDIA INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 152. GCC CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GCC CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. GCC CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. GCC CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION CONTRAST MEDIA INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS CONTRAST MEDIA INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. G7 CONTRAST MEDIA INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 175. G7 CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 176. G7 CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. G7 CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. G7 CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. G7 CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. NATO CONTRAST MEDIA INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 183. NATO CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 184. NATO CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. NATO CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. NATO CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. NATO CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CONTRAST MEDIA INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES CONTRAST MEDIA INJECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA CONTRAST MEDIA INJECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA CONTRAST MEDIA INJECTORS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA CONTRAST MEDIA INJECTORS MARKET SIZE, BY MOBILITY, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA CONTRAST MEDIA INJECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA CONTRAST MEDIA INJECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA CONTRAST MEDIA INJECTORS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA CONTRAST MEDIA INJECTORS MARKET SIZE, BY GASTROENTEROLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA CONTRAST MEDIA INJECTORS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)